Cover Image
Market Research Report

North America Immunosuppressant Drugs Market Forecast 2019-2028

Published by Inkwood Research Product code 939708
Published Content info 105 Pages
Delivery time: 2-3 business days
Price
Back to Top
North America Immunosuppressant Drugs Market Forecast 2019-2028
Published: June 1, 2020 Content info: 105 Pages
Description

KEY FINDINGS

The North America immunosuppressant drugs market is projected to record growth at a CAGR of 3.19% during the forecast period, 2019-2028. The surge in demand for organ transplantation, as a result of increasing organ failure incidences, is the influential factor in stimulating market growth.

MARKET INSIGHTS

The North America immunosuppressant drugs market growth analysis involves market evaluation of Canada and the United States. Canada has the presence of major pharmaceutical companies. The pharmaceutical industry of the country comprises of an ecosystem of local and multinational companies. A large part of the Canadian population is affected by autoimmune diseases. Sjogren's syndrome is one such autoimmune disorder that is prevalent in Canada. Immunosuppressant drugs are an instrumental part of treatment for such autoimmune disorders. Over the years, there has been an increase in the NDD (NDD, or neurological determination of death) donors and a decrease in the DCD (donation after cardio-circulatory death) donors. DCD was practiced in the country since 2006. There have also been significant variations in the type of organs being transplanted. Such factors are attributed to the growth of the market under study.

COMPETITIVE INSIGHTS

Some of the eminent companies progressing in the market are Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Astellas Pharma Inc, AbbVie Inc, Cipla Ltd, etc.

Our report offerings include:

Explore key findings of the overall market

  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Table of Contents
Product Code: 31793

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. DEVELOPMENT OF IMMUNOSUPPRESSANT DRUGS
  • 3.2. MARKET DEFINITION
  • 3.3. KEY DRIVERS
    • 3.3.1. INCREASE IN THE NUMBER OF AUTOIMMUNE DISORDERS
    • 3.3.2. RISE IN ORGAN TRANSPLANTATION
    • 3.3.3. GROWTH IN THE PHARMACEUTICAL INDUSTRY
  • 3.4. KEY RESTRAINTS
    • 3.4.1. SIDE EFFECTS OF IMMUNOSUPPRESSANT DRUGS
    • 3.4.2. LACK OF AWARENESS ABOUT ORGAN DONATION

4. KEY ANALYTICS

  • 4.1. KEY INVESTMENT INSIGHTS
  • 4.2. PORTER'S FIVE FORCE ANALYSIS
    • 4.2.1. BUYER POWER
    • 4.2.2. SUPPLIER POWER
    • 4.2.3. SUBSTITUTION
    • 4.2.4. NEW ENTRANTS
    • 4.2.5. INDUSTRY RIVALRY
  • 4.3. OPPORTUNITY MATRIX
  • 4.4. VENDOR LANDSCAPE

5. MARKET BY DISTRIBUTION CHANNEL

  • 5.1. HOSPITAL PHARMACIES
  • 5.2. RETAIL PHARMACIES
  • 5.3. ONLINE PHARMACIES

6. MARKET BY END-USER

  • 6.1. ORGAN TRANSPLANTATION
  • 6.2. AUTOIMMUNE DISORDERS
  • 6.3. OTHERS

7. MARKET BY DRUG CLASS

  • 7.1. CORTICOSTEROIDS
  • 7.2. MONOCLONAL ANTIBODIES
  • 7.3. CALCINEURIN INHIBITORS
  • 7.4. MTOR INHIBITORS
  • 7.5. OTHERS

8. GEOGRAPHICAL ANALYSIS

  • 8.1. NORTH AMERICA
    • 8.1.1. UNITED STATES
    • 8.1.2. CANADA

9. COMPANY PROFILES

  • 9.1. ABBVIE INC
  • 9.2. ALLERGAN PLC (ACQUIRED BY ABVIE INC)
  • 9.3. ASTELLAS PHARMA INC
  • 9.4. BRISTOL-MYERS SQUIBB COMPANY
  • 9.5. CIPLA LTD
  • 9.6. DR. REDDY'S LABORATORIES LTD
  • 9.7. F HOFFMANN-LA ROCHE AG
  • 9.8. GLAXOSMITHKLINE PLC
  • 9.9. INTAS PHARMACEUTICALS LTD (ACCORD HEALTHCARE LTD)
  • 9.10. JANSSEN PHARMACEUTICALS NV (JHONSON & JHONSON)
  • 9.11. MYLAN NV
  • 9.12. NOVARTIS INTERNATIONAL AG (SANDOZ)
  • 9.13. PFIZER INC
  • 9.14. SANOFI SA
  • 9.15. VELOXIS PHARMACEUTICALS

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - IMMUNOSUPPRESSANT DRUGS
  • TABLE 2: SIDE EFFECTS OF IMMUNOSUPPRESSANT DRUGS
  • TABLE 3: TOP 15 POSITIVE NET EXPORTS COUNTRIES AND NEGATIVE NET EXPORTS FOR DRUGS & MEDICINES COUNTRIES
  • TABLE 4: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 5: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 6: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 7: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 8: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY CLASS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 9: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY CLASS, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 10: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 11: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: DEVELOPMENT OF IMMUNOSUPPRESSANT DRUGS
  • FIGURE 2: KEY INVESTMENT INSIGHTS
  • FIGURE 3: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 4: OPPORTUNITY MATRIX
  • FIGURE 5: VENDOR LANDSCAPE
  • FIGURE 6: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2019
  • FIGURE 7: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY HOSPITAL PHARMACIES, 2019-2028 (IN $ MILLION)
  • FIGURE 8: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY RETAIL PHARMACIES, 2019-2028 (IN $ MILLION)
  • FIGURE 9: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY ONLINE PHARMACIES, 2019-2028 (IN $ MILLION)
  • FIGURE 10: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, GROWTH POTENTIAL, BY END-USER, IN 2019
  • FIGURE 11: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY ORGAN TRANSPLANTATION, 2019-2028 (IN $ MILLION)
  • FIGURE 12: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY AUTOIMMUNE DISORDERS, 2019-2028 (IN $ MILLION)
  • FIGURE 13: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
  • FIGURE 14: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, GROWTH POTENTIAL, BY CLASS, IN 2019
  • FIGURE 15: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY CORTICOSTEROIDS, 2019-2028 (IN $ MILLION)
  • FIGURE 16: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY MONOCLONAL ANTIBODIES, 2019-2028 (IN $ MILLION)
  • FIGURE 17: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY CALCINEURIN INHIBITORS, 2019-2028 (IN $ MILLION)
  • FIGURE 18: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY MTOR INHIBITORS, 2019-2028 (IN $ MILLION)
  • FIGURE 19: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
  • FIGURE 20: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 21: UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 22: CANADA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
Back to Top